Telemedicine Company Owner Pleads Guilty to $46 Million Medicare Fraud Scheme

A telemedicine company owner pleaded guilty to a $46 million Medicare fraud scheme involving medically unnecessary genetic tests and prescriptions.

Telemedicine Company Owner Pleads Guilty to $46 Million Medicare Fraud Scheme A telemedicine company owner pleaded guilty to a $46 million Medicare fraud scheme involving medically unnecessary genetic tests and prescriptions. Aaron Rafferty March 28, 2026 Key Takeaways: A telemedicine company owner pleaded guilty to operating a $46 million Medicare fraud scheme involving medically unnecessary genetic tests and prescriptions. The scheme used telehealth consultations as a billing vehicle, routing orders through complicit physicians who never examined patients. The DOJ prosecution is part of a broader federal crackdown on healthcare fraud that has accelerated in 2026. A telemedicine company owner pleaded guilty to a $46 million Medicare fraud scheme built on the same infrastructure designed to make healthcare more accessible. The scheme worked like this: the company billed Medicare for genetic tests and compound prescriptions that were medically unnecessary. Telehealth consultations served as the billing vehicle. Physicians who signed the orders never examined the patients. The company collected from Medicare. The patients received tests they didn't need. The physicians received fees for services they didn't perform. That number, $46 million, is worth sitting with. It represents thousands of fraudulent claims processed through a system that relies on trust between providers, patients, and the federal government. The trust was the vulnerability. The telehealth platform was the mechanism. The Department of Justice prosecution is one of a growing number of federal healthcare fraud cases targeting telemedicine operators. The model is consistent across cases: a legitimate-sounding digital health company, a network of complicit or negligent physicians, and a billing pipe